While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.
A tie-up between four leading pharmaceutical companies, the UK government and a health charity has created the world’s largest genetic research project. LSIPR’s Rory O’Neill looks at a new frontier for life sciences.
An intervention by Russia’s IP ombudsman seeks to solve the validity issue over secondary patents, but is it needed, asks Maxim Sobolev of Rouse.
There is no doubting the importance of next year’s CRISPR appeal, but any conclusions about the parties’ prior art have consequences for elsewhere too, say Catherine Coombes and Emma Longland of HGF.
The Actavis v ICOS UK Supreme Court judgment was a bitter pill to swallow, but is it really the end of dosage patents? Richard Wells and Stephanie Pilkington of Potter Clarkson review the situation.
Filing a divisional patent application in Brazil needs a keen understanding of the process and flexibility in the system, as Kene Gallois and Luis Felipe Maciel da Silva of Daniel Law explain.
The Delhi High Court has taken the unusual step of directing the IPAB to hear an urgent matter with the help of a technical expert from the Plant Varieties Protection Authority. Vidisha Garg of Anand and Anand reports.
Held during Boston’s week-long Biotech festival, BioPharm America promises its 4,500 delegates excellent knowledge, networking, and deal opportunities, says Guadalupe Rodriguez of EBD Group.
For all the importance of the role of government and private sector bodies in the realisation of precision medicine, it’s important not to lose sight of the interests and concerns of those precision medicine intends to treat—the patients and public at large, write Daniel Lim and Anna Jackson of Kirkland & Ellis.
In future, the more efficient targeting of treatments to specific patient populations that will actually benefit from them, could offset the price of more expensive but well targeted and effective treatments that will be suitable for increasingly smaller patient populations. Daniel Lim and Anna Jackson of Kirkland & Ellis explain.